Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.

Thuy DoanLee WordenArmin HinterwirthAhmed M ArzikaRamatou MalikiAmza AbdouLina ZhongCindi ChenCatherine CookElodie LebasKieran S O'BrienCatherine E OldenburgEric D ChowTravis C PorcoMarc LipsitchJeremy D KeenanThomas M Lietman

Published in: The New England journal of medicine (2020)

Among villages assigned to receive mass distributions of azithromycin or placebo twice yearly for 4 years, antibiotic resistance was more common in the villages that received azithromycin than in those that received placebo. This trial showed that mass azithromycin distributions may propagate antibiotic resistance. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02047981.).

Keyphrases

phase iii
clinical trial
double blind
study protocol
randomized controlled trial
open label
monte carlo